Table 6.
Relation between serum aminotransferase concentration and mortality from liver disease in men by follow up period. Figures are relative risks* (95% confidence intervals)
| Year 1993-6 | Year 1997-2000 | |
|---|---|---|
| Serum aspartate aminotransferase level (IU/I):
|
|
|
| <20 | 1.0 (0.6 to 1.7) | 1.0 (0.6 to 1.8) |
| 20-29 | 1.8 (1.3 to 2.4) | 3.3 (2.6 to 4.3) |
| 30-39 | 6.4 (4.8 to 8.7) | 10.0 (7.6 to 13.0) |
| 40-49 | 17.2 (11.8 to 25.2) | 36.3 (26.9 to 49.1) |
| 50-99 | 46.8 (36.5 to 59.9) | 89.4 (71.9 to 111.2) |
| ≥100 | 61.6 (38.9 to 97.6) | 178.8 (115.5 to 254.9) |
| Serum alanine aminotransferase level (IU/I):
|
|
|
| <20 | 1.0 (0.6 to 1.6) | 1.0 (0.7 to 1.5) |
| 20-29 | 3.1 (2.4 to 4.2) | 2.7 (2.1 to 3.4) |
| 30-39 | 12.5 (9.7 to 16.3) | 7.6 (5.8 to 9.9) |
| 40-49 | 21.4 (15.2 to 30.2) | 17.8 (13.1 to 24.2) |
| 50-99 | 27.5 (20.4 to 36.9) | 31.6 (25.0 to 40.0) |
| ≥100 | 30.0 (16.0 to 55.9) | 82.8 (58.4 to 117.5) |
*
Adjusted for age, body mass index, smoking status, alcohol consumption, plasma glucose, serum total cholesterol, blood pressure, and family history of liver disease.